Venous blood

Know Labs to Present Clinical Research at the 2024 American Association of Clinical Endocrinology Annual Meeting

Retrieved on: 
Giovedì, Maggio 9, 2024
Health, Medical Devices, Technology, Clinical Trials, Research, Wearables, Mobile Technology, Science, FDA, Know Labs, Diabetes, CGM, AACE, Venous blood, Machine learning, CDT, Annual general meeting, Medical device

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an oral abstract presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting in New Orleans, Louisiana on May 9, 2024 from 11:15 a.m. – 11:30 a.m. CDT.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an oral abstract presentation at the American Association of Clinical Endocrinology (AACE) Annual Meeting in New Orleans, Louisiana on May 9, 2024 from 11:15 a.m. – 11:30 a.m. CDT.
  • During 2024, as the Company continues on the path toward FDA clearance, Know Labs will deploy the KnowU™, its wearable, non-invasive continuous glucose monitor (CGM) in large-scale, external clinical trials while advancing model techniques and making refinements to the device.
  • These new studies will help determine the technology’s performance throughout continuous wear, in more real-world environments, and within more extreme glycemic ranges (below 70 mg/dL and above 350 mg/dL).
  • To stay updated on the latest results, visit www.knowlabs.co/research-and-development .

Know Labs to Present Clinical Research at the 2024 American Physiology Summit

Retrieved on: 
Venerdì, Aprile 5, 2024
Health, Medical Devices, Diabetes, Biometrics, Health Technology, Clinical Trials, Biotechnology, CGM, MARD, Venous blood, Know Labs, Machine, APS, Mayo Clinic, Blood, American Physiological Society, FDA

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit in Long Beach, California on April 4-7, 2024.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced it has been selected for an abstract poster presentation at the American Physiological Society (APS) Summit in Long Beach, California on April 4-7, 2024.
  • At the previous APS Summit, Know Labs presented results from its peer-reviewed, proof-of-principle study conducted in collaboration with Mayo Clinic, which assessed the accuracy of its RF dielectric sensor in identifying different analytes in vitro, proving a 100% accuracy rate in these tests.
  • Since then, Know Labs has published several clinical studies demonstrating the stability, repeatability, and accuracy of its non-invasive continuous blood glucose monitor.
  • Most recently, Know Labs announced interim results from its first clinical research protocol involving people with diabetes, using venous blood as a comparative reference and a machine learning model trained on data collected in a lab setting, which resulted in an overall MARD of 11.1%.

Boston Heart Diagnostics Launches Industry-Leading Small-Volume Product Line with over 40 Dried Blood Spot Tests

Retrieved on: 
Mercoledì, Agosto 3, 2022
Disease, Collection, Patient, Men's Health, Blood, Multimedia, Health care, View, Venous blood, Health, Pharmaceutical industry, Medical device, Medical imaging, Eurofins Scientific

FRAMINGHAM, Mass., Aug. 3, 2022 /PRNewswire/ -- Boston Heart Diagnostics Corporation, a clinical laboratory within the Eurofins network of companies, announced its launch today of a broad range of tests with a dried blood spot collection.

Key Points: 
  • FRAMINGHAM, Mass., Aug. 3, 2022 /PRNewswire/ -- Boston Heart Diagnostics Corporation, a clinical laboratory within the Eurofins network of companies, announced its launch today of a broad range of tests with a dried blood spot collection.
  • These innovative and convenient tests, available to healthcare providers and their patients, are especially valuable when venous blood draws are inconvenient or inaccessible.
  • Boston Heart dried bloodspot testing is a highly accurate and reliable process, has been extensively validated, and has an average correlation of 96% with liquid venous blood.
  • For more information on Boston Heart Diagnostics, please visit www.BostonHeartDiagnostics.com
    View original content to download multimedia: https://www.prnewswire.com/news-releases/boston-heart-diagnostics-launch...

GBS Inc. Announces Institutional Review Board Approval to Initiate Clinical Trial at Sutter Health Mills-Peninsula Medical Center

Retrieved on: 
Giovedì, Marzo 31, 2022
Johns Hopkins, Pacific Northwest Diabetes Research Institute, Private Securities Litigation Reform Act, LinkedIn, Quality control, Principal, Mills-Peninsula Medical Center, Interim, Johns Hopkins Hospital, NEW, MPMC, Trial of the century, Forward-looking statement, Sex, Adult, IRB, Sutter Health, Venous blood, GBS, U.S. Securities and Exchange Commission, Security (finance), Diabetes, Securities Exchange Act of 1934, Securities Act of 1933, Nasdaq, COVID-19, GLOBE, Drug Quality and Security Act, Department, Institutional review board, Terminology, Blood, Patient, Collection, Medical imaging, Medical device, Sintering, Pathology, Glucose

NEW YORK, March 31, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced it has obtained Institutional Review Board (IRB) approval to initiate subject enrollment at the Diabetes Research Institute of Sutter Health’s Mills-Peninsula Medical Center (MPMC) in San Mateo, California. The study design is intended to support the clinical development of its next-generation Saliva Glucose Biosensor.        

Key Points: 
  • We are delighted to be working with David C. Klonoff, M.D., Medical Director of the Diabetes Research Institute at Mills-Peninsula Medical Center and our Principal Investigator for this study.
  • GBS will be working with:
    Sutter Health, Mills-Peninsula Medical Center to enroll approximately 40 adult subjects diagnosed with type 2 diabetes in the study.
  • Sutter Health, Mills-Peninsula Medical Center will also collect and freeze saliva and blood samples for subsequent analysis by other partners.
  • GBS Inc. is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners.

Novo Integrated Sciences Signs Memorandum of Understanding with Boditech Med, a Global Point-of-Care Testing Leader, to Market and Distribute in North America

Retrieved on: 
Martedì, Marzo 29, 2022
Biotechnology, Practice Management, Pharmaceutical, Alternative Medicine, Health, Marketing, Communications, Fitness & Nutrition, Pillar, Company, Biomarker, CCI, Population, NASDAQ, Partnership, Leadership, American University of Integrative Sciences, Marketing, Health, Board, Point-of-care testing, Cancer, Medicine, CEO, Food, U.S. Securities and Exchange Commission, Quality of life, Technology, Infection, Safety, Intention, Securities Exchange Act of 1934, Ecosystem, International, Workflow, Securities Act of 1933, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Acceleration, Science, Drug Quality and Security Act, Solution, Venous blood, Blood, Patient, Security (finance), Pharmaceutical industry, Medical device, Healthcare, KOSDAQ

Founded in South Korea in 1998, Boditech markets and sells more than 90 biomarker products in 120 countries.

Key Points: 
  • Founded in South Korea in 1998, Boditech markets and sells more than 90 biomarker products in 120 countries.
  • Boditech intends to bring lower-cost, rapid testing that covers many critical areas of medicine, from cardiac health to cancer, to North America.
  • With Boditechs planned expansion into North America, together we will improve the health and safety of patients and the effectiveness and workflow of clinicians.
  • Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting-edge advancement in patient first platforms.

Boditech Med, Global Point-of-Care Testing Leader, to Expand to U.S., North America

Retrieved on: 
Venerdì, Marzo 18, 2022
Biomarker, Point-of-care testing, Cancer, Medicine, CEO, Health, Food, Quality of life, Safety, Infection, Time, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, GLOBE, Venous blood, Blood, Patient, Partnership, Medical device, Pharmaceutical industry, KOSDAQ

MIAMI, March 18, 2022 (GLOBE NEWSWIRE) -- Boditech Med, a global leader in point-of-care testing with more than 90 biomarker products, announced today that it will establish operations in North America.

Key Points: 
  • MIAMI, March 18, 2022 (GLOBE NEWSWIRE) -- Boditech Med, a global leader in point-of-care testing with more than 90 biomarker products, announced today that it will establish operations in North America.
  • Founded in South Korea in 1998, Boditech Med markets and sells more than 90 biomarker products in 120 countries.
  • Boditech intends to bring lower-cost, rapid testing that covers many critical areas of medicine, from cardiac health to cancer, to the country.
  • Boditech Med is a global leader in point-of-care testing with a decades-long track record of improving health and quality of life through innovative in-vitro diagnostic solutions.

LivaNova Receives FDA 510(k) Clearance for B-Capta, the New In-Line, Blood-Gas Monitoring System Integrated Into the S5 Heart-Lung Machine

Retrieved on: 
Martedì, Aprile 20, 2021
FDA, Surgery, Medical devices, Health, Cardiology, LivaNova, Medicine, Medical equipment, Blood, Cardiopulmonary bypass, XC2, Venous blood, Blood gas test, Branches of biology, Health care

b'LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for B-Capta\xc2\xae, the new in-line, blood-gas monitoring system integrated into the market-leading S5\xc2\xae heart-lung machine (HLM).

Key Points: 
  • b'LivaNova PLC (NASDAQ:LIVN), a market-leading medical technology and innovation company, today announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for B-Capta\xc2\xae, the new in-line, blood-gas monitoring system integrated into the market-leading S5\xc2\xae heart-lung machine (HLM).
  • The system is designed to easily and accurately monitor arterial and venous blood gas parameters even during long and complex pediatric and adult cardiopulmonary bypass procedures.
  • Headquartered in London, LivaNova employs approximately 4,000 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals and healthcare systems worldwide.
  • These statements include, but are not limited to, statements regarding B-Capta.

Blood Collection Device Manufacturer Boston Microfluidics Appoints Linh Hoang, MD, PhD as CEO

Retrieved on: 
Martedì, Giugno 9, 2020
Medical specialties, Blood tests, Branches of biology, Hematology, Medicine, Blood, Transfusion medicine, Biotechnology, Microfluidics, Fingerstick, Venous blood, Venipuncture

"Laboratory diagnostics inform a majority of medical decisions, and now more than ever, blood collection must evolve to enable at-home solutions.

Key Points: 
  • "Laboratory diagnostics inform a majority of medical decisions, and now more than ever, blood collection must evolve to enable at-home solutions.
  • Options such as BMF's collection device (in development) enables at-home collection which is a critical piece to ramping up serology testing.
  • The study demonstrates equivalency in analytical performance between venous blood draw and finger prick blood collection, which is enabled by the BMF's device.
  • Boston Microfluidics develops simple, intuitive, and needle-free blood collection devices designed to greatly simplify and revolutionize blood testing globally.